DxU Iris Nominated for the SelectScience Scientists' Choice Awards®

Laboratory scientists around the world are invited to vote for the Best New Clinical Product of 2021.
DxU Iris Nominated for the SelectScience Scientists' Choice Awards®

Best New Clinical Product of 2021

SelectScience’s annual Scientists' Choice Awards celebrates the most innovative and effective technologies of the past year chosen by the people who actually use them – the scientists. Scientists worldwide have the opportunity to recognize the instruments, assays, tools and consumables that have made the most difference to their work.

Thanks to our loyal customers, we’re delighted to announce the DxU Iris Workcell Automated Urinalysis Solution has been nominated in the Best New Clinical Product of 2021 category!

The innovative and reliable DxU Iris Workcell Automated Urinalysis Solution is streamlining workflow, reducing manual microscopic review, and standardizing high-throughput processing. Featuring load-and-go, walkaway capabilities and Edit-Free Release technology, the DxU Iris takes the interruptions out of your urinalysis workflow.

Cast your vote

Voting is now open. Take a moment to view the shortlists, as nominated by clinical scientists and healthcare professionals worldwide, and cast your vote for the Best New Clinical Product.

Voting closes Tuesday, July 19, 2022. All scientists who vote for Best New Clinical Products will be entered into a drawing for a chance to win a $500/£400/450 € Amazon Gift Card from SelectScience.

Editorial Team
Editorial Team
The Beckman Coulter editorial team brings you timely news and resources focused on elevating clinical laboratory performance and advancing patient care.

Related Articles

Get to Know Advantaged Workflows

Get to Know Advantaged Workflows

It takes the right combination of efficiency, accuracy, technology, and clinical expertise to transform a workflow into a unique advantage—and we’re here to help find the right combination for you.
Blood-Based Biomarkers and the Future of Alzheimer’s Disease Diagnostics

Blood-Based Biomarkers and the Future of Alzheimer’s Disease Diagnostics

We sat down with our own Alzheimer’s disease and dementia subject matter expert, Dr. Arindam Ghosh, to learn the potential of blood-based biomarkers to transform the approach to Alzheimer’s disease diagnosis and management.
Exploring the Potential Role of Blood-Based Biomarkers in Identifying and Monitoring Alzheimer's Disease

Exploring the Potential Role of Blood-Based Biomarkers in Identifying and Monitoring Alzheimer's Disease

At the 2024 Clinical Trials in Alzheimer’s Disease (CTAD 2024) conference in Madrid, Spain, discussed the promise of blood-based diagnostic biomarkers.